| Volume 23, 2019 Articles |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
PreScription: The Cost of Information
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 4
|
An Outlook on the European and Italian Rules to Guarantee Magistral Formulas
Selmin Francesca, Casiraghi Antonella, Musazzi Umberto M, Fortini Marco, Minghetti Paola
|
Jan/Feb 2019
Pg. 6-12
|
The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 2
Williams LaVonn A
|
Jan/Feb 2019
Pg. 14-21
|
Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Zur Eyal
|
Jan/Feb 2019
Pg. 23-31
|
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
|
Jan/Feb 2019
Pg. 32-33
|
Basics of Compounding: Standardization of Compounded Medications
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 35-44
|
Quality Control and Basics of Sterile Compounding: Attempting to Avoid Out-of-Specification Results and Patient Harm in Sterile Compounding
Martin Matt
|
Jan/Feb 2019
Pg. 47-49
|
Calculations
Stockton Shelly J
|
Jan/Feb 2019
Pg. 50
|
Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 52
|
Ketoprofen 20-mg/mL in SyrSPend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 53
|
Lidocaine Hydrochloride, Diphenhydramine Hydrochloride, Aluminum Hydroxide–Magnesium Hydrochloride–Simethicone Mouthwashes
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 54
|
Magnesium Sulfate and Lidocaine Hydrochloride Injection in Prefilled Syringes
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 55
|
Methimazole 5 mg/0.1 mL in Pluronic Lecithin Organogel Gel, Veterinary
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 56
|
Minoxidil 1-mg/mL in Ora-Plus and Ora-Sweet SF Suspension
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 57
|
Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 58
|
Orodispersible Film
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 59
|
Piperacillin 10 mg/mL in 0.9% Sodium Chloride Bladder Irrigation
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 60
|
Thiamine Hydrochloride 100 mg/mL in SurSPend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 61
|
Chemical Stability of Progesterone in Compounded Oral Rapid-dissolving Tablets
Sayre Casey L, Cox Christopher, Velazquez Gabriel, Le Minh Thi, Nguyen Amy Hong, Ramos Marjorie, Burrows Anna, Yellepeddi Venkata Kashyap
|
Jan/Feb 2019
Pg. 62-64
|
Transdermal Delivery of Metformin Hydrochloride from a Semisolid Vehicle
Polonini Hudson, Lopes Cândido Paulo José, Andrade Junquiera Laura, Loures Sharlene, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson
|
Jan/Feb 2019
Pg. 65-69
|
Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Miller Valicia, Morris Tommy C, Graves Richard A
|
Jan/Feb 2019
Pg. 70-76
|
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy
Laque Larissa C, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C
|
Jan/Feb 2019
Pg. 77-81
|
Stability Assessment of Topical Amitriptyline Extemporaneously Compounded with Lipoderm Base, PLO Gel Mediflo 30, and Emollient Cream
Shakshuki Ayah, Agu Remigius U
|
Jan/Feb 2019
Pg. 82-87
|
PreScription: Compounding with Cannabidiol
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 92
|
Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
|
Mar/Apr 2019
Pg. 94-104
|
Nimodipine Compounded Oral Suspension: A True Documented Medical Need
McElhiney Linda F
|
Mar/Apr 2019
Pg. 106-111
|
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia
Zur Eyal
|
Mar/Apr 2019
Pg. 113-119
|
Patient Access Is a Patient Safety Issue
Pore David
|
Mar/Apr 2019
Pg. 120-121
|
Basics of Compounding for Sterile, Nonsterile, and Quality Control Compounding: Process Analytical Technology: Appropriate for Sterile and Nonsterile Compounding?
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 123-130
|
Basics of Compounding: Summary of the Official United States Pharmacopeia Monographs for Compounded Preparations
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 135-143
|
Calculations
Stockton Shelly J, Drinnon Stephen D
|
Mar/Apr 2019
Pg. 144
|
Acetaminophen 50% Pluronic Lecithin Organogel Gel
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 146
|
Amlodipine 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 147
|
Captopril 0.8 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 148
|
Dexamethasone 2 mg/g Topical Paste, Veterinary
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 149
|
Ketoprofen 10% in Pluronic Lecithin Organogel
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 150
|
Perphenazine 0.5 mg/mL Oral Liquid
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 151
|
Rosuvastatin 20 mg/mL Oral Suspension
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 152
|
Tacrolimus 0.5 mg/mL in Oral Mix Suspension
Allen Loyd V Jr
|
Mar/Apr 2019
Pg. 153
|
Towards the Importance of a Roller Mill in Compounding Practice: An Experimental Approach
Polonini Hudson, Loures da Silva Sharlene, Batista Patrício Fernando, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson
|
Mar/Apr 2019
Pg. 154-156
|
Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Morris Tommy C, Graves Richard A
|
Mar/Apr 2019
Pg. 157-162
|
Evaluation of the Physicochemical Stability of Amiodarone Hydrochloride in Syringes for the Intensive Care Unit
Lardinois Benjamin, Dimitriou Alexandre, Delcave Charlotte, Jamart Jacques, Bihin Benoît, Soumoy Laura, Hecq Jean-Daniel, Galanti Laurence M
|
Mar/Apr 2019
Pg. 163-166
|
Physicochemical Stability of Extemporaneously Prepared Methylcobalamin Injections in the Presence and Absence of Preservative and the Impact of Light Exposure
Ip Kendice, Banov Daniel, Bassani Gus, Morgan Latisha
|
Mar/Apr 2019
Pg. 167-175
|
PreScription: Honesty/Ethics in Professions: The Gallup Polls
Allen Loyd V Jr
|
May/Jun 2019
Pg. 180
|
How to Develop and Maintain a Hazardous Drug List
Dillon L Rad
|
May/Jun 2019
Pg. 182-186
|
Summary of Educational Offerings Provided by Compounding Support Companies in 2019
Stevens J Tyler
|
May/Jun 2019
Pg. 188-191
|
Compounding for Patients with Polycystic Ovarian Syndrome (Stein-Leventhal Syndrome)
Riepl Mike
|
May/Jun 2019
Pg. 192-199
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Zur Eyal
|
May/Jun 2019
Pg. 200-207
|
Can We Fix It?
Brunner Scott
|
May/Jun 2019
Pg. 208-209
|
Summary of Quality-Control Testing for Sterile and Nonsterile Compounded Preparations, Part 1: Physical and Chemical Testing
Allen Loyd V Jr
|
May/Jun 2019
Pg. 211-216
|
Basics of Sterile Compounding: Vehicles Used in Sterile Compounding
Allen Loyd V Jr
|
May/Jun 2019
Pg. 221-228
|
Calculations
Stockton Shelly J
|
May/Jun 2019
Pg. 229
|
Aripiprazole 1 mg/mL in Methylcellulose 1% Syrup Oral Suspension
Allen Loyd V Jr
|
May/Jun 2019
Pg. 230
|
Chloroquine Phosphate 15 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2019
Pg. 231
|
Clopidogrel 5 mg/mL in a Sugar-Free Syrup
Allen Loyd V Jr
|
May/Jun 2019
Pg. 232
|
Flunisolide Nasal Spray
Allen Loyd V Jr
|
May/Jun 2019
Pg. 233
|
Mebeverine Hydrochloride 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
May/Jun 2019
Pg. 234
|
Methotrexate 2-mg/mL Oral Solution
Allen Loyd V Jr
|
May/Jun 2019
Pg. 235
|
Sildenafil 2.5 mg/mL in Ora-Plus:Ora-Sweet
Allen Loyd V Jr
|
May/Jun 2019
Pg. 236
|
Valsartan 16-mg/mL Oral Suspension
Allen Loyd V Jr
|
May/Jun 2019
Pg. 237
|
Evaluation of the Quality of Sterile Compounding Videos Available on the YouTube Video-sharing Website
Sluggett Janet K, Johnson Michelle J, Zamani Mazdak, Kastango Eric S, Bodnar Mark, Cantor Peter, Hobbs Jodie G, Reynolds Karen J, Sluggett Andrew J
|
May/Jun 2019
Pg. 238-244
|
Trends of Extemporaneous Drug Prescription in Latvia in 2017
Kiselova Olga, Maurina Baiba, Sidlovska Venta, Rogovska Irena
|
May/Jun 2019
Pg. 245-249
|
Compounding and Comparative Study of a Superior, Faster, and More Adaptable Lidocaine Dental Gel Formulation
Rashid Mamoon, Hossain Mohammad Faisal, Nounou Mohamed, Rahman Mehbuba, Sarkar Sushanta, Adeyemo Akinola, Mullins Randy
|
May/Jun 2019
Pg. 250-257
|
An Exploratory Study of Suboxone (Buprenorphine/Naloxone) Film Splitting: Cutting Methods, Content Uniformity, and Stability
Reindel Kristin L, DeAngelis Michael J, Ferrara Alexander S, Conn Kelly M, Phillips Elizabeth M, Corigliano Anthony T, Zhao Fang
|
May/Jun 2019
Pg. 258-263
|
PreScription: Temperatures by Degrees
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 268
|
Contamination Control in Compounding Areas
Mulder Kyle, Gonzales Ben A
|
Jul/Aug 2019
Pg. 271-278
|
Mean Kinetic Temperature for Controlled Room Temperature Drug Storage: Official Definitions and Example Calculations
Newton David W
|
Jul/Aug 2019
Pg. 281-287
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Zur Eyal
|
Jul/Aug 2019
Pg. 288-293
|
Now Is the Time for All Good Compounders to Come to the Aid of Their Profession: What You Do Right Now to Advance Compounding's Advocacy Priorities Can Help Assure Your Profession's Future
Brunner Scott
|
Jul/Aug 2019
Pg. 294-296
|
Summary of Quality-Control Testing for Sterile and Nonsterile Compounded Preparations, Part 2: Microbiological Testing
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 299-303
|
Basics: Excipients Used in Nonsterile Compounding, Part 1
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 305-311
|
Calculations
Stockton Shelly J, Drinnon Stephen D
|
Jul/Aug 2019
Pg. 312-313
|
Aripiprazole 1 mg/mL in Oral-Plus:Ora-Sweet (1:1) Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 314
|
Candesartan Cilexetil 1 mg/mL in Syrup NF or Vehicle for Oral Solution USP
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 315
|
Domperidone 5 mg/mL in Oral Mix
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 316
|
Lorazepam 1 mg/mL in Anhydrous Organic Solvent System
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 317
|
Morphine Sulfate 0.2-mg/mL Solution Stored in Amber Oral Plastic Syringes
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 318
|
Rifampin 25 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2019
Pg. 319
|
Long-term Physicochemical Stability of Concentrated Solutions of Sodium Valproate in Polypropylene Syringes for Administration in the Intensive Care Unit
Lardinois Benjamin, Baltzis Alexandre, Braibant Maximilien, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence
|
Jul/Aug 2019
Pg. 320-323
|
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
de Lafuente Yanina, García Mónica Cristina, Jiminez-Kairuz Alvaro
|
Jul/Aug 2019
Pg. 324-331
|
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy
Glaser Rebecca L, York Anne E
|
Jul/Aug 2019
Pg. 325-339
|
Development and Validation of a Stability-indicating High-performance Liquid Chromatographic Method for Quantification of Progesterone in Compounded Glycerinated Gelatin Troches
Burrows Anna C, Yellepeddi Venkata Kashyap, Snyder Spencer, Wakefield Meagan, Jackson David, Huynh Johnny, Nguyen Khoa, Sayre Casey L
|
Jul/Aug 2019
Pg. 340-350
|
Erratum: Zur E. Topical Treatment of Primary Focal Hyperhidrosis, Part 2. IJPC 2019; 23(2):94-104.
|
Jul/Aug 2019
Pg. 351
|
Erratum: Kiselova O, Maurina B, Sidlovska V et al. Trends of Extemporaneous Drug Prescription in Latvia in 2017. IJPC 2019; 23(3): 245-249.
|
Jul/Aug 2019
Pg. 351
|
PreScription: Regulations, Laws, Standards, Guidelines, Procedures, Etc
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 356
|
Compounded Cyclophosphamide and Piroxicam for the Treatment of a Canine Peripheral Nerve Sheath Tumor: A Case Report
Pope George, Daleo Charles, Batson SL
|
Sep/Oct 2019
Pg. 358-364
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
|
Sep/Oct 2019
Pg. 366-375
|
Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus
Zur Eyal
|
Sep/Oct 2019
Pg. 376-381
|
Threading the Needle
Brunner Scott
|
Sep/Oct 2019
Pg. 383-385
|
Quality Control: Hand and Glove Sanitizing in Sterile Compounding, Part 1
Greeson Nicole MH, Mixon William, Huslage Kirk, Stiegel Matthew A, Thomann Wayne R
|
Sep/Oct 2019
Pg. 387-391
|
Basics: Excipients Used in Nonsterile Compounding, Part 2
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 393-396
|
Sterile Basics: Pharmaceutical Waters Used in Sterile and Nonsterile Compounding
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 399-402
|
Calculations
Stockton Shelly J
|
Sep/Oct 2019
Pg. 404
|
Allopurinol 20 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 406
|
Amitriptyline Hydrochloride 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 407
|
Dipyridamole 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 408
|
Omeprazole 2 mg/mL in SyrSpend SF Alka (Reconstituted)
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 409
|
Oxandrolone 3 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 410
|
Sorafenib Capsules for Pediatric Use
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 411
|
Valsartan 4 mg/mL in Vehicle for Oral Solution USP
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 412
|
Verapamil Hydrochloride 50 mg/mL in Ora-Plus:Ora-Sweet (1:1)
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 413
|
Stability of Furosemide 5 mg/mL in Polypropylene Syringes
van der Schaar JAJ, Grouls R, Franssen EJF, Crul M
|
Sep/Oct 2019
Pg. 414-417
|
Measurement of Free Iodine in Different Formulations of Povidone-Iodine Eye Drops 5%
Berisa Prado Silvia, Riestra Ayora Ana Cristina, Trelles Campa Adrián
|
Sep/Oct 2019
Pg. 418-421
|
The Current Landscape of Veterinary Compounding in the Pharmacy Setting
Gochenauer Alexandria E, Holmes Erin R, Barber Katie E, Forsythe Lauren R
|
Sep/Oct 2019
Pg. 422-427
|
The Current Landscape of Veterinary Compounding in the Veterinary Setting
Gochenauer Alexandria E, Rishniw Mark, Holmes Erin R, Forsythe Lauren R
|
Sep/Oct 2019
Pg. 428-433
|
Long-term Physiochemical Stability of Concentrated Solutions of Salbutamol (Albuterol) in Polypropylene Syringes for Use in the Intensive Care Unit and in Obstetrics
Lardinois Benjamin, Baltzis Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence
|
Sep/Oct 2019
Pg. 434-437
|
Erratum: McNulty JP, Hahn K. Compounded oral ketamine for severe depression, anxiety, and pain in a hospice patient with end-stage chronic obstructive pulmonary disease, cardiopulmonary failure, and severe : A case report. IJPC. 2012; 16(5): 364–368.
|
Sep/Oct 2019
Pg. 438
|
Erratum: Stevens JT. Summary of educational offerings provided by compounding support companies in 2019. IJPC. 2019; 23(3): 188–191.
|
Sep/Oct 2019
Pg. 438
|
PreScription: As Things Change….
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 444
|
Primary Engineering Controls in Pharmaceutical Compounding, Part 1: Unidirectional-airflow Workstations, Compounding Aseptic Isolators, and Compounding Aseptic Containment Isolators
Mulder Kyle
|
Nov/Dec 2019
Pg. 447-452
|
How to Qualify Container Closure Systems for Intended Use, Part 1
Kim Amy A, Gehrmann Matthew R, McCaw James, McAndrew T Page
|
Nov/Dec 2019
Pg. 454-461
|
Are You Part of the Solution or Part of the Problem?
Brunner Scott
|
Nov/Dec 2019
Pg. 462-464
|
Quality Control: Hand and Glove Sanitizing in Sterile Compounding, Part 2
Greeson Nicole MH, Mixon William, Huslage Kirk, Stiegel Matthew A, Thomann Wayne R
|
Nov/Dec 2019
Pg. 467-471
|
Basics: Excipients Used in Nonsterile Compounding, Part 3: Preservatives
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 472-477
|
Intravenous Admixture Preparation Considerations, Part 1: Overview of Series on Personnel Selection for Intravenous Admixture Compounding
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 478-482
|
Calculations
Stockton Shelly J, Stover Emily M
|
Nov/Dec 2019
Pg. 484
|
Gabapentin 50-mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 486
|
Prednisolone Sodium Phosphate 1.4 mg/mL in SyrSpend SR pH4, Cherry Flavored
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 487
|
Pregabaline 20 mg/mL in SyrSpend SR pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 488
|
Riboflavin 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 489
|
Sulfasalazine 100 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 490
|
Tacrolimus Monohydrate 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 491
|
Tadalafil 5 mg/mL in Oral-Plus:Ora-Sweet (1:1)
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 492
|
Ursodiol 30 mg/mL in SyrSpend SF Cherry Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 493
|
Verapmail Hydrochloride 50 mg/mL in SyrSpend SF
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 494
|
Zonisamide 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Nov/Dec 2019
Pg. 495
|
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Shakshuki Ayah, Agu Remigius U
|
Nov/Dec 2019
Pg. 496-503
|
Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid
Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
|
Nov/Dec 2019
Pg. 504-510
|
Evaluation of Containment Ventilated Enclosure Performance in Absence of Negative Pressure Containment Secondary Engineering Control
Hutson Chad, Day A J
|
Nov/Dec 2019
Pg. 511-518
|
Physicochemical Stability of Compounded Amlodipine Besylate Suspensions in PCCA Base, SuspendIt
Graves Richard A, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Swopes Demikka, Morris Tommy C, Pramar Yashoda V
|
Nov/Dec 2019
Pg. 519-527
|
| Return to Top |
